Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections

American Journal of Managed Care

Volumn 6, Issue 23 SUPPL., 2000, Pages

  Nicolau, D P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; TROVAFLOXACIN;

AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL COUNT; COMMUNITY; COMORBIDITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG ELIMINATION; ERADICATION THERAPY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMMUNITY-ACQUIRED INFECTIONS; DECISION MAKING; DRUG UTILIZATION; HUMANS; MACROLIDES; RESPIRATORY TRACT INFECTIONS; UNITED STATES;

EID: 0034526914     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
2. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: Focus on antibacterial agents
3. Pharmacokinetic and pharmacodynamic principles in antibiotic usage
4. Killing and regrowth of bacteria in vitro: A review
5. Using pharmacodynamic/pharmacokinetic surrogate markers in clinical practice: Optimizing antibiotic therapy in respiratory tract infections
6. Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: Focus on the fluoroquinolones
7. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
8. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin
9. Pneumococcal meningitis during intravenous ciprofloxacin therapy
10. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
11. Treating community-acquired pneumonia with once-daily gatifloxacin vs once daily levofloxacin
12. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations
13. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for the cephalosporins
14. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: Implications for breakpoint determinations
15. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
16. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection
17. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance
18. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
19. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers